Moneycontrol PRO
UPCOMING EVENT:Join us for New HorAIzon from Oct 6-7, 2pm and be a part of exciting conversations on tech & innovation

Buy Ipca Laboratories; target of Rs 2400: ICICI Direct

ICICI Direct is bullish on Ipca Laboratories has recommended buy rating on the stock with a target price of Rs 2400 in its research report dated August 11, 2020.

August 12, 2020 / 03:29 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Ipca Laboratories

Revenues grew 42.3% YoY to Rs 1534.4 crore (I-direct estimate: Rs 1287.8 crore) due to one-time opportunity of ~Rs 259 crore for HCQS/chloroquine supplies in both API & formulation segments. Export formulations grew 89.4% YoY to Rs 463.6 crore and API segment grew 72.0% YoY to Rs 513.3 crore. Domestic revenues grew 8.1% YoY to Rs 489.4 crore. EBITDA margins improved to 38.3% vs. 18.3% in Q1FY20 (I-direct estimate: 20.0%) due to lower operational expenditure. EBITDA grew 198.4% YoY to Rs 588.3 crore (I-direct estimate: Rs 257.6 crore). PAT grew 244% YoY to Rs 445.9 crore (I-direct estimate: Rs 180 crore) mainly due to a strong operational performance and lower tax rate (18.3% against 22.4% in Q1FY20).


Ipca will continue to remain a compelling bet on the back of well-rounded growth prospects for FY20–22E- sales, EBITDA, PAT CAGR of 14%, 29%, 39%, respectively. We arrive at our target price of Rs 2400 (26x FY22E EPS of Rs 92.3).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Aug 12, 2020 03:29 pm

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark